IPO registrations (S-1, F-1) · Registrants
Biofrontera AG
- SEC CIK
- 1712641 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2018-01-12, last 2018-02-13; 1 initial registration, 5 amendments
- Outcome
- Final prospectus filed 2018-02-15; declared effective 2018-02-13
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- 2M
- Business address
- HEMMELRATHER WEG 201, Leverkusen, 2M D-51377
- EDGAR entity type
- other
Offering terms
- Final price
- $9.88 per ADS (424B4 filed 2018-02-15, an initial public offering)
- Shares sold
- 1,215,000
- Gross proceeds
- $12,004,200 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol BFRA
- Lead underwriters
- The Benchmark Company (384,785 shares)
- Syndicate
- Dawson James (364,500); Lake Street Capital Markets (364,500); ViewTrade (101,215)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2018-01-12 | F-1 | F-1 (foreign registration) | Biofrontera AG | 0001615774-18-000305 ↗ |
| 2018-01-26 | F-1/A | F-1/A (amendment) | Biofrontera AG | 0001615774-18-000575 ↗ |
| 2018-01-31 | F-1/A | F-1/A (amendment) | Biofrontera AG | 0001615774-18-000718 ↗ |
| 2018-02-06 | F-1/A | F-1/A (amendment) | Biofrontera AG | 0001615774-18-000863 ↗ |
| 2018-02-12 | F-1/A | F-1/A (amendment) | Biofrontera AG | 0001615774-18-001003 ↗ |
| 2018-02-13 | F-1/A | F-1/A (amendment) | Biofrontera AG | 0001615774-18-001079 ↗ |
| 2018-02-13 | EFFECT | EFFECT (declared effective) | Biofrontera AG | 9999999995-18-000430 ↗ |
| 2018-02-15 | 424B4 | 424B4 (final prospectus) | Biofrontera AG | 0001615774-18-001233 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-02-13 | F-1/A | registration statement | 1,210,000 | - | Nasdaq BFRA | 3 | primary document; shares headline, cover names 3 | document ↗ | ||
| 2018-02-15 | 424B4 | final prospectus | $9.88 | 1,215,000 | $12,004,200 | Nasdaq BFRA | 4 | primary document; price table, shares headline, proceeds table, underwriting table 4, cover names 3 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Others with the same interests
SIC industry Pharmaceutical Preparations, 2M first:
- MorphoSys AG 2M
- Affimed N.V. 2M
- InflaRx N.V. 2M
- CURAXIS PHARMACEUTICAL Corp 2Q
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
In other datasets, the same topic (Health) in 2M:
- Form D issuer: ATAI Life Sciences AG (Form D private offerings)
Interests: Pharmaceutical Preparations · Health